Untreated Narcolepsy & Excessive Daytime Sleepiness
Unmanaged narcolepsy floods the day with irresistible, sudden sleep attacks.
- 1 in 2,000: Prevalence (estimated US cases)
- ~90%: Orexin neuron loss (in type 1 narcolepsy)
- 8+: Sleep attacks per day (without treatment)
- ~8–15 yrs: Diagnosis delay (symptom onset to diagnosis)
What drives the sleepiness
Loss of hypothalamic orexin neurons destabilizes wake-sleep boundaries.
Daily impact
Sleep attacks strike during driving, meals, and conversation.
Untreated narcolepsy carries accident risk comparable to driving drunk.
Why treat wakefulness directly
Stimulant-like wakefulness agents became the first-line daytime therapy.
Starting Dose — Modafinil 100–200mg
Treatment begins low, dosed once each morning to match the wake cycle.
- 100–200mg: Typical starting dose (modafinil, once daily)
- ~15 hrs: Half-life (modafinil)
- 2–4 hrs: Time to peak plasma (after morning dose)
- 150–250mg: Armodafinil dose (the R-enantiomer)
Mechanism
Modafinil weakly blocks dopamine reuptake, boosting wake-promoting circuits.
Why mornings
Morning dosing lines coverage up with the waking day.
Late dosing risks insomnia given the long 15-hour half-life.
Early monitoring
Clinicians track alertness, headache, and blood pressure closely.
Partial Response — Afternoon Sleepiness Persists
Morning alertness improves while coverage fades before the day ends.
- ~40%: Responders at starting dose (adequate control)
- ~60%: Afternoon symptom return (of patients)
- ~4 pts: ESS score improvement (partial, below target)
- <10: Target ESS score (Epworth Sleepiness Scale)
Why coverage fades
Drug levels decline hours before the evening wake window ends.
Clinical signal
Persistent afternoon sleepiness signals the dose is too low.
A stagnant Epworth score below target flags under-dosing.
Next step
Guidelines recommend stepwise dose increases, not switching drugs.
Dose Titration Toward the 400mg Ceiling
Dose climbs in defined steps until daytime alertness holds steady.
- +100mg: Titration increment (per adjustment step)
- 1–2 wks: Titration interval (between increases)
- 400mg: Maximum daily dose (modafinil ceiling)
- 250mg: Armodafinil ceiling (once daily)
Titration logic
Each step is held long enough to judge steady-state response.
Split dosing option
A second midday dose can extend afternoon coverage.
Splitting the dose helps without exceeding the daily ceiling.
Watching tolerability
Higher doses raise risk of insomnia, headache, and jitteriness.
Optimized Control — Alertness Sustained All Day
The titrated dose keeps wakefulness steady from morning into evening.
- <10: ESS at optimal dose (normalized range)
- 0–1: Sleep attacks per day (residual episodes)
- ~65–80%: Patients reaching control (with titration)
- Every 6–12 mo: Maintenance reviews (ongoing dose checks)
Stable coverage
The optimized dose keeps alertness above threshold until bedtime.
Quality of life
Driving, work, and social function return toward normal.
Optimal titration balances full alertness against minimal side effects.
Long-term care
Periodic review keeps the dose matched to changing needs.